Novo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...

To say that pharmaceutical giant Novo Nordisk (NYSE: NVO) has had a tumultuous relationship with telehealth company Hims & Hers Health (NYSE: HIMS) in the past year would be a bit of an understatement ...

May 21 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab said on Thursday it is now offering Canadians a generic version of semaglutide, the active ingredient in Novo Nordisk's (NOVOb.CO), opens ...

Hims & Hers announced it will offer generic semaglutide through its direct-to-consumer virtual care platform to eligible customers in Canada, following Novo Nordisk's loss of Canadian patent ...

Digital health firm Hims & Hers' stock plummeted on Tuesday on weak first-quarter earnings. Hims reported a net loss of $92 million in the first quarter, up from $50 million last year. The company ...

Hims & Hers Health (HIMS) reported Q1 2026 earnings on May 11 and the stock dropped. Revenue of $608.1 million missed the $616.9 million estimate. The GAAP loss came in at $0.40 per share, far below ...

News broke yesterday that the FDA is proposing to exclude the globally best-selling prescription drug molecules semaglutide, tirzepatide and liraglutide from its 503B bulk list, "finding no clinical ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...